US20150265631A1 - Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation - Google Patents

Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation Download PDF

Info

Publication number
US20150265631A1
US20150265631A1 US14/722,320 US201514722320A US2015265631A1 US 20150265631 A1 US20150265631 A1 US 20150265631A1 US 201514722320 A US201514722320 A US 201514722320A US 2015265631 A1 US2015265631 A1 US 2015265631A1
Authority
US
United States
Prior art keywords
cyclodextrin
progesterone
tablet
composition
total weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/722,320
Inventor
Lorenzo Bellorini
Luca Nocelli
Giorgio Zoppetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altergon SA
Original Assignee
Altergon SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altergon SA filed Critical Altergon SA
Priority to US14/722,320 priority Critical patent/US20150265631A1/en
Publication of US20150265631A1 publication Critical patent/US20150265631A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A61K47/48969—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Definitions

  • the present invention refers to a new pharmaceutical composition for the sublingual administration of progesterone, and to a method for its preparation.
  • Progesterone is a steroid hormone that is naturally secreted by the ovaries in the second half of the menstrual cycle of fertile women of reproductive age; it is used for therapeutic purposes, e.g. in hormone replacement therapy for menopausal women, in oral contraceptives and for regulating the menstrual cycle.
  • progesterone is severely reduced when it is administered orally, however, due to a more limited bioavailability deriving from its solubility in water and its rapid degradation by the liver; these two factors contribute to a very poor absorption of the active ingredient in the gastrointestinal tract.
  • progesterone be administered via absorption in the oral cavity, where it is less affected by a rapid metabolism in the liver than when it is absorbed in the gastrointestinal tract. Said mode of administration generally gives rise to only modest haematic levels of progesterone unless it is administered in the form of its water-soluble derivative.
  • rapid disintegration we mean a time preferably lasting no more than two minutes.
  • the subject of the present invention is therefore a pharmaceutical composition for the sublingual administration of progesterone associated with a cyclodextrin, characterised in that it is in the form of a rapidly-disintegrating tablet comprising excipients capable of releasing CO 2 in the sublingual site.
  • bicarbonate such as sodium bicarbonate
  • suitable acid such as citric acid
  • progesterone associated or combined with a cyclodextrin we mean a complexing derivative such as those described in U.S. Pat. No. 4,596,795.
  • a further object or the invention is a method used to prepare the aforesaid pharmaceutical composition, which can be achieved by means of the following stages:
  • FIG. 1 shows a diagram comparing the concentration (ng/ml) of progesterone in the serum against the time after the sublingual administration of 20 mg of active ingredient using the tablets prepared as in example 1 (invention) and example 2 (reference).
  • excipients capable of releasing CO 2 in the sublingual site are citric acid and sodium bicarbonate.
  • the quantity of citric acid contained in the composition of the invention is, for instance, comprised between 5 and 20% w/w of the total weight of the composition, and preferably amounts to 10% w/w.
  • the quantity of bicarbonate contained in the composition of the invention is, for instance, comprised between 5 and 20% w/w of the total weight of the composition, and preferably amounts to 12% w/w.
  • the bicarbonate contained in the composition of the invention is preferably sodium bicarbonate.
  • the molar ratio of the progesterone to the cyclodextrin is between 1 and 2.
  • a cyclodextrin suitable for use in the present composition may be, for instance, either ⁇ -cyclodextrin or 2-hydroxypropyl- ⁇ -cyclodextrin; the composition of the invention preferably contains 2-hydroxypropyl- ⁇ -cyclodextrin.
  • the quantity of cyclodextrin contained in the composition shall preferably be between 27 and 40% w/w of the total weight of the composition.
  • the pharmaceutical compositions according to the invention may comprise further pharmacologically suitable excipients chosen from among those conventionally used in pharmaceutical preparations to obtain a composition in the form of a rapidly-disintegrating tablet.
  • the present pharmaceutical composition in tablet form, though it is hard enough to enable it to retain its shape and remain intact so that the product can be packaged and preserved, when it is placed under the tongue it nonetheless disintegrates rapidly, becoming completely disintegrated within a time generally between 60 and 120 seconds.
  • pharmacokinetic studies (described in more detail in Example 3) have demonstrated an approximately 30% increase in the bioavailability of the progesterone in the compositions according to the present invention by comparison with similar compositions for sublingual administration that lack the pair of effervescent excipients, such as citric acid and sodium bicarbonate.
  • compositions according to the invention can be prepared to contain various unit doses of progesterone, for instance, between 5 and 30 mg of progesterone, and preferably amounting to 20 mg.
  • the mixture is agitated for 45 minutes at ambient temperature;
  • the second semiprocessed product is prepared according to steps 2 and 3 in a stainless steel container (B) and transferred to a dissolver (A) prepared according to steps 1 and 3;
  • Ingredients 1), 2), 3), 4), 5), 6) and 9) are premixed and sieved through a wire sieve with 1 mm net mesh holes and loaded in a mixer.
  • Component 8 is separately sieved through a 0.5 mm wire sieve and loaded in the mixer.
  • the ingredients are mixed for 25 minutes at a speed of 20 rpm/60′′.
  • Component 9 is sieved through a 0.2 mm wire sieve and loaded in the mixer.
  • the powder is unloaded and compressed with a round punch 16 mm in diameter, setting a mean weight of 665 mg ⁇ 3% and a mean hardness of 35 N ⁇ 3N.
  • the tablets are blister-packed in a suitable format and placed in cardboard boxes.
  • Ingredients 1), 2), 3), 4) and 7) are premixed and sieved through a wire sieve with 1 mm net mesh holes and loaded in a mixer.
  • Component 6 is separately sieved through a 0.5 mm wire sieve and loaded in the mixer.
  • the ingredients are mixed for 25 minutes at a speed of 20 rpm/60′′.
  • Component 5 is sieved through a 0.2 mm wire sieve and loaded in the mixer.
  • the powder is unloaded and compressed with a round punch 16 mm in diameter, setting a mean weight of 665 mg ⁇ 3% and a mean hardness of 35 N ⁇ 3N.
  • the tablets are blister-packed in a suitable format and placed in cardboard boxes.
  • FIG. 1 The diagram in the attached drawing ( FIG. 1 ) compares the concentration (ng/ml) of progesterone in the serum against the time after the sublingual administration of 20 mg of active ingredient using the tablets prepared as in example 1 (invention) and example 2 (reference).
  • the two curves plotted in the diagram represent the mean (+SD) of the values obtained in three subjects treated as described above.
  • the curve relating to example 1 shows an approximately 30% greater mean bioavailability than the curve relating to example 2.

Abstract

A pharmaceutical composition is described for the sublingual administration of progesterone in the form of a rapidly-disintegrating tablet, which is capable of promoting a greater bioavailability of the progesterone; a method for preparing said pharmaceutical composition is also described.

Description

    FIELD OF THE INVENTION
  • The present invention refers to a new pharmaceutical composition for the sublingual administration of progesterone, and to a method for its preparation.
    • STATE OF THE ART
  • Progesterone is a steroid hormone that is naturally secreted by the ovaries in the second half of the menstrual cycle of fertile women of reproductive age; it is used for therapeutic purposes, e.g. in hormone replacement therapy for menopausal women, in oral contraceptives and for regulating the menstrual cycle.
  • Various methods for administering progesterone are known, from the parenteral to the vaginal, to the oral, the last of these being by far the most readily acceptable and comfortable for the patients, especially if they have to undergo lengthy periods of treatment.
  • The therapeutic efficacy of progesterone is severely reduced when it is administered orally, however, due to a more limited bioavailability deriving from its solubility in water and its rapid degradation by the liver; these two factors contribute to a very poor absorption of the active ingredient in the gastrointestinal tract.
  • To overcome these problems, it has been suggested that progesterone be administered via absorption in the oral cavity, where it is less affected by a rapid metabolism in the liver than when it is absorbed in the gastrointestinal tract. Said mode of administration generally gives rise to only modest haematic levels of progesterone unless it is administered in the form of its water-soluble derivative.
  • The U.S. Pat. No. 4,596,795, for instance, describes a formulation in tablets for administering progesterone buccally or sublingually in the oral cavity, in which the progesterone is combined with specific beta-cyclodextrins. In fact, when combined with these compounds, progesterone forms inclusion complexes that are soluble in an aqueous environment, thereby favouring its bioavailability.
  • In the case of its sublingual administration, this patent indicates the need for the tablet to disintegrate, which takes several minutes.
    • SUMMARY
  • According to the present invention, it has now surprisingly been discovered that adding certain excipients to a composition comprising progesterone and a cyclodextrin gives rise to a powder that can be compressed to obtain a tablet which is sufficiently compact for packaging but that nonetheless disintegrates rapidly when administered sublingually, and that said rapidly-disintegrating tablet is able, when administered sublingually, to promote a greater bioavailability of the progesterone than a tablet lacking said excipients.
  • By rapid disintegration, we mean a time preferably lasting no more than two minutes.
  • The subject of the present invention is therefore a pharmaceutical composition for the sublingual administration of progesterone associated with a cyclodextrin, characterised in that it is in the form of a rapidly-disintegrating tablet comprising excipients capable of releasing CO2 in the sublingual site.
  • For said purpose it preferably comprises a bicarbonate, such as sodium bicarbonate, and a suitable acid, such as citric acid.
  • According to the present invention, by progesterone associated or combined with a cyclodextrin, we mean a complexing derivative such as those described in U.S. Pat. No. 4,596,795.
  • A further object or the invention is a method used to prepare the aforesaid pharmaceutical composition, which can be achieved by means of the following stages:
      • a) sieving the excipients and the raw material;
      • b) mixing;
      • c) compressing the mixture to produce said finished tablet.
  • Characteristics and advantages of the pharmaceutical composition according to the present invention are illustrated in more detail in the description that follows.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows a diagram comparing the concentration (ng/ml) of progesterone in the serum against the time after the sublingual administration of 20 mg of active ingredient using the tablets prepared as in example 1 (invention) and example 2 (reference).
    •  DETAILED DESCRIPTION OF THE INVENTION
  • Reference is made below to the non-limiting case in which said excipients capable of releasing CO2 in the sublingual site are citric acid and sodium bicarbonate.
  • The quantity of citric acid contained in the composition of the invention is, for instance, comprised between 5 and 20% w/w of the total weight of the composition, and preferably amounts to 10% w/w.
  • The quantity of bicarbonate contained in the composition of the invention is, for instance, comprised between 5 and 20% w/w of the total weight of the composition, and preferably amounts to 12% w/w.
  • The bicarbonate contained in the composition of the invention is preferably sodium bicarbonate.
  • According to a preferred embodiment of the invention, the molar ratio of the progesterone to the cyclodextrin is between 1 and 2.
  • A cyclodextrin suitable for use in the present composition may be, for instance, either β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin; the composition of the invention preferably contains 2-hydroxypropyl-β-cyclodextrin.
  • The quantity of cyclodextrin contained in the composition shall preferably be between 27 and 40% w/w of the total weight of the composition.
  • In addition to the active ingredient (progesterone), a cyclodextrin and the pair of excipients with an effervescent action (citric acid and bicarbonate), the pharmaceutical compositions according to the invention may comprise further pharmacologically suitable excipients chosen from among those conventionally used in pharmaceutical preparations to obtain a composition in the form of a rapidly-disintegrating tablet.
  • The present pharmaceutical composition in tablet form, though it is hard enough to enable it to retain its shape and remain intact so that the product can be packaged and preserved, when it is placed under the tongue it nonetheless disintegrates rapidly, becoming completely disintegrated within a time generally between 60 and 120 seconds.
  • Moreover, pharmacokinetic studies (described in more detail in Example 3) have demonstrated an approximately 30% increase in the bioavailability of the progesterone in the compositions according to the present invention by comparison with similar compositions for sublingual administration that lack the pair of effervescent excipients, such as citric acid and sodium bicarbonate.
  • The compositions according to the invention can be prepared to contain various unit doses of progesterone, for instance, between 5 and 30 mg of progesterone, and preferably amounting to 20 mg.
  • The following examples are given as a non-limiting illustration of the present invention.
    • EXAMPLE OF THE PREPARATION METHOD 1 Formulation:
  • 1) hydroxypropyl-β-cyclodextrin, batch E0033 kg 13.5
    Kleptose (HPBCD)
    2) progesterone micron. batch L00025494 kg 1.35
    3) distilled water of 13.06.05 kg 55.4625
    • Method for Preparing the Solution to lyophilize:
  • 1) kg 42.2625 of distilled water are transferred to a dissolver (A) with a capacity of 200 L;
  • 2) the first semiprocessed product is prepared in a separate stainless steel container (B);
  •
    distilled water kg 6.6
    hydroxypropyl-β-cyclodextrin, Kleptose (HPBCD) kg 6.75
  • and agitated for 20 minutes at ambient temperature;
  • the deaerated solution appears clear and contains no residues;
  • 3) progesterone micron. kg 0.675 is added to the solution prepared according to step 2;
  • the mixture is agitated for 45 minutes at ambient temperature;
  • the resulting solution is transferred to a dissolver prepared according to step 1;
  • 4) the second semiprocessed product is prepared according to steps 2 and 3 in a stainless steel container (B) and transferred to a dissolver (A) prepared according to steps 1 and 3;
  • 5) the final solution is mixed for 10 minutes in a 200 L dissolver; the resulting solution is clear and contains no air bubbles; approximately 40 mL of solution are drawn off for analyses;
  • the solution is placed in the lyophilizer;
  • 6) the solution is forced through a 0.46 μm column filter under a pressure of 2 bar of anhydrous air;
  • 7) the solution is placed on disposable high-density polyethylene mats in a continuous flow (16—maintaining a bulk thickness of 1 cm);
  • 8) the product is lyophilized;
  • 9) the resulting bulk product is ground in an oscillating granulator and passed through a 1 mm sieve;
  • 13.9 kg of end product are obtained;
  • 10) the product is placed in three aluminium containers, which are then sealed.
  • The resulting powder has the following characteristics:
  • Bulk humidity when unloaded from the mats 0.9%.
  • Humidity after grinding 1.5%.
  • Bulk density after pouring =0.26 g/ml
  • Bulk density after compacting =0.32 g/ml
  • Particle size distribution:
  • 95% between 50 and 800 μm
  • mean =260 μm
    • Example 1 Method for Preparing Tablets for the Sublingual Administration of Progesterone According to the Invention
  • The single components are separately weighed and labelled as follows:
  • Weight in g
    1 Progesterone complex (as described 1507
    in the example preparation method 1)
    2 Polyvinylpyrrolidone CL 253.45
    3 Citric acid anhydrous powder 445.25
    4 Sodium bicarbonate powder 548
    5 Calcium silicate 616.5
    6 Sorbitol 787.75
    7 Sodium stearyl fumarate 34.25
    8 E951 137
    9 Flavouring 226.05
    TOTAL 4555.25
  • Ingredients 1), 2), 3), 4), 5), 6) and 9) are premixed and sieved through a wire sieve with 1 mm net mesh holes and loaded in a mixer.
  • Component 8) is separately sieved through a 0.5 mm wire sieve and loaded in the mixer.
  • The ingredients are mixed for 25 minutes at a speed of 20 rpm/60″.
  • Component 9) is sieved through a 0.2 mm wire sieve and loaded in the mixer.
  • Mixing proceeds with the other ingredients for 5 minutes at a speed of 20 rpm/60″.
  • The powder is unloaded and compressed with a round punch 16 mm in diameter, setting a mean weight of 665 mg ±3% and a mean hardness of 35 N ±3N.
  • The tablets are blister-packed in a suitable format and placed in cardboard boxes.
  • The resulting tablets have the following characteristics:
  • mean weight =660.4, mean titre =103.1% d.d., hardness =33N and disintegration time =100 sec.
    • Example 2 (COMPARISON) Method for Preparing Tablets for the Sublingual Administration of Progesterone Without Citric Acid and Bicarbonate
  • The single components are separately weighed and labelled as follows:
  • Weight in g
    1 Progesterone complex (as described in 44
    the example preparation method 1)
    2 Polyvinylpyrrolidone CL 7.4
    3 Calcium silicate 18
    4 Sorbitol 52
    5 Sodium stearyl fumarate 1
    6 E951 4
    7 Flavouring 6.6
    TOTAL 133
  • Ingredients 1), 2), 3), 4) and 7) are premixed and sieved through a wire sieve with 1 mm net mesh holes and loaded in a mixer.
  • Component 6) is separately sieved through a 0.5 mm wire sieve and loaded in the mixer.
  • The ingredients are mixed for 25 minutes at a speed of 20 rpm/60″.
  • Component 5) is sieved through a 0.2 mm wire sieve and loaded in the mixer.
  • Mixing proceeds with the other ingredients for 5 minutes at a speed of 20 rpm/60″.
  • The powder is unloaded and compressed with a round punch 16 mm in diameter, setting a mean weight of 665 mg ±3% and a mean hardness of 35 N ±3N.
  • The tablets are blister-packed in a suitable format and placed in cardboard boxes.
  • The resulting tablets have the following characteristics:
  • mean weight =664, mean titre =101.1% d.d., hardness =32N and disintegration time =90 sec.
    • Example 3 Pharmacokinetic Study
  • A preliminary pharmacokinetic study was conducted to compare the administration of tablets according to the invention, obtained as described in example 1, with those prepared for comparison as described in example 2.
  • The diagram in the attached drawing (FIG. 1) compares the concentration (ng/ml) of progesterone in the serum against the time after the sublingual administration of 20 mg of active ingredient using the tablets prepared as in example 1 (invention) and example 2 (reference).
  • The two curves plotted in the diagram represent the mean (+SD) of the values obtained in three subjects treated as described above.
  • Clearly, the curve relating to example 1 shows an approximately 30% greater mean bioavailability than the curve relating to example 2.

Claims (15)

1-23. (canceled)
24. A method to significantly increase the sublingual bioavailability of a progesterone fast disintegrating tablet without significantly modifying the tablet disintegration time, characterized by including in said tablet: (a) progesterone combined with a cyclodextrin, and (b) citric acid and sodium bicarbonate, each present in an amount between 5 and 20% of the total weight of the tablet composition.
25. The method according to claim 24, characterized in that said tablet comprises citric acid amounting to 10% w/w of the total weight of the composition.
26. The method according to claim 24, characterized in that said tablet comprises bicarbonate amounting to 12% w/w of the total weight of the composition.
27. The method according to claim 24, characterized in that said cyclodextrin is chosen from either β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin.
28. The method according to claim 24, characterized in that the molar ratio of said progesterone to said cyclodextrin is between 1 and 2.
29. The method according to claim 24, characterized in that the content of cyclodextrin is between 27 and 40% w/w of the total weight of the composition.
30. The method according to claim 24, characterized in that when placed under the tongue, said tablet disintegrates completely within a time approximately between 60 and 120 seconds.
31. A method to significantly increase the sublingual bioavailability of a progesterone fast disintegrating tablet without significantly modifying the tablet hardness, characterized by including in said tablet: (a) progesterone combined with a cyclodextrin, and (b) citric acid and sodium bicarbonate, each present in an amount between 5 and 20% of the total weight of the tablet composition.
32. The method according to claim 31, characterized in that said tablet comprises citric acid amounting to 10% w/w of the total weight of the composition.
33. The method according to claim 31, characterized in that said tablet comprises bicarbonate amounting to 12% w/w of the total weight of the composition.
34. The method according to claim 31, characterized in that said cyclodextrin is chosen from either β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin.
35. The method according to claim 31, characterized in that the molar ratio of said progesterone to said cyclodextrin is between 1 and 2.
36. The method according to claim 31, characterized in that the content of cyclodextrin is between 27 and 40% w/w of the total weight of the composition.
37. The method according to claim 31, characterized in that when placed under the tongue, said tablet disintegrates completely within a time approximately between 60 and 120 seconds.
US14/722,320 2007-10-10 2015-05-27 Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation Abandoned US20150265631A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/722,320 US20150265631A1 (en) 2007-10-10 2015-05-27 Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI2007A001971 2007-10-10
IT001971A ITMI20071971A1 (en) 2007-10-10 2007-10-10 PHARMACEUTICAL COMPOSITION FOR SUBLINGUAL ADMINISTRATION OF PROGESTERONE, AND METHOD FOR ITS PREPARATION
PCT/EP2008/063595 WO2009047321A2 (en) 2007-10-10 2008-10-10 A sublingual effervescent tablet of progesterone associated with cyclodextrin
US73407810A 2010-04-07 2010-04-07
US14/722,320 US20150265631A1 (en) 2007-10-10 2015-05-27 Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US12/734,078 Division US9066858B2 (en) 2007-10-10 2008-10-10 Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation
PCT/EP2008/063595 Division WO2009047321A2 (en) 2007-10-10 2008-10-10 A sublingual effervescent tablet of progesterone associated with cyclodextrin

Publications (1)

Publication Number Publication Date
US20150265631A1 true US20150265631A1 (en) 2015-09-24

Family

ID=40313810

Family Applications (2)

Application Number Title Priority Date Filing Date
US12/734,078 Active 2030-11-09 US9066858B2 (en) 2007-10-10 2008-10-10 Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation
US14/722,320 Abandoned US20150265631A1 (en) 2007-10-10 2015-05-27 Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/734,078 Active 2030-11-09 US9066858B2 (en) 2007-10-10 2008-10-10 Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation

Country Status (13)

Country Link
US (2) US9066858B2 (en)
EP (1) EP2217219B1 (en)
JP (1) JP2011500534A (en)
KR (1) KR20100077159A (en)
CN (1) CN101854923B (en)
AT (1) ATE536865T1 (en)
CA (1) CA2701857C (en)
DK (1) DK2217219T3 (en)
ES (1) ES2378917T3 (en)
IT (1) ITMI20071971A1 (en)
PL (1) PL2217219T3 (en)
PT (1) PT2217219E (en)
WO (1) WO2009047321A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011021805A2 (en) 2009-08-18 2011-02-24 주식회사 엘지화학 Novel compound, catalyst composition comprising same, and method for preparing a cyclic olefin polymer using same
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
EP2802311B1 (en) * 2011-10-25 2018-12-12 Expermed S.A. Sublingual pharmaceutical composition containing an antihistamine agent and method for the preparation thereof
ITMI20122027A1 (en) 2012-11-28 2014-05-29 Altergon Sa ORAL STEROID AND HP¿C ORCHOUS WATER SOLUTIONS WITH OPTIMIZED BIOAVAILABILITY
CN103877048A (en) * 2014-03-26 2014-06-25 邵娜 Orally-disintegrating progesterone tablet and preparation method thereof
ITUB20161027A1 (en) 2016-02-24 2017-08-24 Altergon Sa Oromucosal pharmaceutical preparations with high bioavailability based on cyclodextrin and sucralose
WO2018117855A1 (en) * 2016-12-20 2018-06-28 X-Ing As Effervescent lozenge
NO20171457A1 (en) * 2016-12-20 2018-06-21 X Ing As Effervescent lozenge
US11253488B2 (en) * 2017-09-06 2022-02-22 pHase Pharmaceuticals LLC Sublingual epinephrine tablets
CN109381424A (en) * 2018-11-21 2019-02-26 南京泽恒医药技术开发有限公司 Water-soluble injection of stable progesterone and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US20040115258A1 (en) * 2000-11-23 2004-06-17 Federico Stroppolo Oral pharmaceutical compositions containing cyclodextrins as taste masking agent

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1419074A (en) * 1972-06-09 1975-12-24 Ici Ltd Process for manufacturing substituted thiophene compounds
AU670454B2 (en) * 1992-11-23 1996-07-18 Pfizer Inc. Regioselective synthesis of 4-chloro-2-thiophenecarboxylic acid
US6323227B1 (en) * 1996-01-02 2001-11-27 Aventis Pharmaceuticals Products Inc. Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US6037340A (en) * 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
DE10061876A1 (en) * 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylated furan and thiophene carboxamides, processes for their preparation, their use as medicaments and pharmaceutical preparations containing them
CA2466375A1 (en) * 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
CA2489433A1 (en) * 2002-07-01 2004-01-08 Pharmacia & Upjohn Company Llc Inhibitors of hcv ns5b polymerase
ATE498395T1 (en) * 2003-12-31 2011-03-15 Cima Labs Inc GENERAL LINEAR EFFORTABLE FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US20040115258A1 (en) * 2000-11-23 2004-06-17 Federico Stroppolo Oral pharmaceutical compositions containing cyclodextrins as taste masking agent

Also Published As

Publication number Publication date
US20100240631A1 (en) 2010-09-23
JP2011500534A (en) 2011-01-06
CA2701857C (en) 2015-03-24
PL2217219T3 (en) 2012-05-31
CA2701857A1 (en) 2009-04-16
WO2009047321A3 (en) 2009-07-09
PT2217219E (en) 2012-03-29
CN101854923A (en) 2010-10-06
ES2378917T3 (en) 2012-04-19
EP2217219B1 (en) 2011-12-14
CN101854923B (en) 2012-04-18
KR20100077159A (en) 2010-07-07
EP2217219A2 (en) 2010-08-18
US9066858B2 (en) 2015-06-30
ITMI20071971A1 (en) 2009-04-11
WO2009047321A2 (en) 2009-04-16
ATE536865T1 (en) 2011-12-15
DK2217219T3 (en) 2012-03-12

Similar Documents

Publication Publication Date Title
US9066858B2 (en) Pharmaceutical composition for the sublingual administration of progesterone, and method for its preparation
US11964055B2 (en) Orodispersible dosage unit containing an estetrol component
TW391880B (en) An oral soluble type compression moulding and its preparation
US11957694B2 (en) Orodispersible dosage unit containing an estetrol component
US20050118272A1 (en) Micronized pharmaceutical or nutraceutical powder with immediate release
US20080145423A1 (en) Chewable tablet and method of formulating
US20110250272A1 (en) Solid, orodispersible and/or dispersible composition, without an excipient of known effect and its process of preparation
WO2007018057A1 (en) Tablet rapidly disintegrating in the oral cavity and method of producing the same
DK2170348T3 (en) SHOWER TABLETS for inhalation
US6274172B1 (en) Therapeutic effervescent compositions
EP0836472B1 (en) Therapeutic effervescent compositions
RU2712123C1 (en) Composition and method for preparing a rapidly soluble antimicrobial drug based on nitrofural (versions)
WO2009123580A1 (en) Chewable tablet and method of formulating
KR102662025B1 (en) Orally dissolvable dosage unit containing estetrol component

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION